Novartis AG - Depositary Receipt (Common Stock)
DE ˙ DB ˙ US66987V1098
121,00 € 0,00 (0,00%)
2026-06-04
DELAT PRIS
SecurityDE:NOTA / Novartis AG - Depositary Receipt (Common Stock)
InstitutionWASHINGTON TRUST Co
Latest Disclosed Ownership4,467 shares
Latest Disclosed Value $ 682,334
WASHINGTON TRUST Co reports 1.67% decrease in ownership of NOTA / Novartis AG - Depositary Receipt (Common Stock)

On April 6, 2026 - WASHINGTON TRUST Co filed a 13F-HR form disclosing ownership of 4,467 shares of Novartis AG - Depositary Receipt (Common Stock) (DE:NOTA) valued at $574,010 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 4,543 shares of Novartis AG - Depositary Receipt (Common Stock). This represents a change in shares of -1.67% during the quarter. The current value of the position is $540,507 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-06 2026-03-31 13F NOVARTIS AG-SPONSORED ADR Equities 66987V109 4,467 -76 -1.67 682 8.95 0.0222
2026-02-10 2025-12-31 13F NOVARTIS AG-SPONSORED ADR Equities 66987V109 4,543 -38 -0.83 626 6.64 0.0199
2025-11-12 2025-09-30 13F NOVARTIS AG-SPONSORED ADR Equities 66987V109 4,581 0 0.00 587 5.96 0.0193
2025-08-08 2025-06-30 13F NOVARTIS AG-SPONSORED ADR Equities 66987V109 4,581 116 2.60 554 11.47 0.0196
2025-04-25 2025-03-31 13F NOVARTIS SPONSORED ADR 66987V109 4,465 -200 -4.29 498 9.71 0.0191
2025-01-30 2024-12-31 13F Novartis SPONSORED ADR 66987V109 4,665 200 4.48 454 -11.70 0.0163
2024-10-25 2024-09-30 13F Novartis SPONSORED ADR 66987V109 4,465 0 0.00 514 8.00 0.0180
2024-07-15 2024-06-30 13F Novartis SPONSORED ADR 66987V109 4,465 10 0.22 475 10.47 0.0174
2024-04-23 2024-03-31 13F Novartis SPONSORED ADR 66987V109 4,455 0 0.00 431 -4.23 0.0158
2024-01-18 2023-12-31 13F Novartis SPONSORED ADR 66987V109 4,455 0 0.00 450 -0.88 0.0178
2023-10-18 2023-09-30 13F Novartis SPONSORED ADR 66987V109 4,455 0 0.00 454 0.89 0.0200
2023-07-27 2023-06-30 13F Novartis SPONSORED ADR 66987V109 4,455 0 0.00 450 9.78 0.0190
2023-05-10 2023-03-31 13F/A-1 Novartis SPONSORED ADR 66987V109 4,455 -300 -6.31 410 -5.10 0.0185
2023-05-04 2023-03-31 13F Novartis SPONSORED ADR 66987V109 4 -4,751 0 0.0173
2023-07-27 2022-12-31 13F/A-1 Novartis SPONSORED ADR 66987V109 4,755 1,500 46.08 431 73.79 0.0201
2023-02-08 2022-12-31 13F Novartis SPONSORED ADR 66987V109 4,755 1,500 0 0.0000
2022-10-14 2022-09-30 13F Novartis SPONSORED ADR 66987V109 3,255 500 18.15 248 6.44 0.0125
2022-07-25 2022-06-30 13F Novartis SPONSORED ADR 66987V109 2,755 -79 -2.79 233 -6.43 0.0109
2022-05-05 2022-03-31 13F Novartis SPONSORED ADR 66987V109 2,834 2 0.07 249 0.40 0.0099
2022-02-09 2021-12-31 13F/A-1 Novartis SPONSORED ADR 66987V109 2,832 2 0.07 248 7.36 0.0093
2022-02-09 2021-12-31 13F Novartis SPONSORED ADR 66987V109 2,832 2 248 0.0087
2021-11-09 2021-09-30 13F Novartis SPONSORED ADR 66987V109 2,830 0 0.00 231 -10.81 0.0065
2021-08-05 2021-06-30 13F Novartis SPONSORED ADR 66987V109 2,830 0 0.00 259 7.02 0.0073
2021-04-28 2021-03-31 13F Novartis SPONSORED ADR 66987V109 2,830 -167 -5.57 242 -14.49 0.0074
2021-02-09 2020-12-31 13F Novartis SPONSORED ADR 66987V109 2,997 270 9.90 283 19.41 0.0091
2020-11-05 2020-09-30 13F Novartis SPONSORED ADR 66987V109 2,727 115 4.40 237 3.95 0.0088
2020-08-04 2020-06-30 13F Novartis SPONSORED ADR 66987V109 2,612 -7,156 -73.26 228 -71.68 0.0095
2020-05-07 2020-03-31 13F Novartis SPONSORED ADR 66987V109 9,768 9,768 805 0.0384
2020-02-12 2019-12-31 13F Novartis SPONSORED ADR 66987V109 0 -6,326 -100.00 0 -100.00
2019-11-06 2019-09-30 13F Novartis SPONSORED ADR 66987V109 6,326 -1,846 -22.59 553 -25.97 0.0296
2019-08-07 2019-06-30 13F NOVARTIS SPONSORED ADR 66987V109 8,172 1,846 29.18 747 44.21 0.0409
2019-05-13 2019-03-31 13F NOVARTIS SPONSORED ADR 66987V109 6,326 -1,455 -18.70 518 -22.46 0.0290
2019-02-11 2018-12-31 13F NOVARTIS SPONSORED ADR 66987V109 7,781 66 0.86 668 0.45 0.0425
2018-11-13 2018-09-30 13F NOVARTIS SPONSORED ADR 66987V109 7,715 50 0.65 665 14.85 0.0356
2018-08-10 2018-06-30 13F Novartis SPONSORED ADR 66987V109 7,665 7,665 579 0.0310
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.